11 kinds of traditional Chinese medicine protection sold more than one billion! The growth rate of two new products is over 20%

In late February, CFDA issued two successive announcements, approving the continued protection of five traditional Chinese medicine protection varieties such as Pianzihuang, and approving five traditional Chinese medicine varieties such as jintange capsule as the first one In recent years, large varieties of traditional Chinese medicine are favored by all parties in the market, especially some products with intellectual property rights, which have more vitality and growth The law of traditional Chinese medicine, which was formally implemented in July last year, also mentioned the protection of traditional intellectual property rights of traditional Chinese medicine In the future, there will be more treasures in the field of traditional Chinese medicine in China According to the data on CFDA's official website, there are more than 200 varieties of traditional Chinese medicine in the market at present Which products are most favored by the market? According to the statistics of minenet, in 2016, there were 28 kinds of traditional Chinese medicine protection products with sales exceeding RMB 500 million, including 11 products with sales exceeding RMB 1 billion Table 1: protected varieties of traditional Chinese medicine with sales exceeding RMB 500 million (unit: RMB 100 million) (data source: CFDA protected varieties of traditional Chinese medicine database and announcement, intranet database; statistical deadline: February 28, 2018) none = "shifumousedownstyle ('shifu_bus_ ')" style = "margin: 1em Auto; padding: 0px; max width: 100%; color: rgb (62, 62, 62); font family:" hiragino sans GB ", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> Xuesaitong for injection (lyophilization) ranks first, with sales volume of more than 5.7 billion in 2016 Figure 1: sales volume of Xuesaitong for injection (lyophilization) from 2015 to 2016 (unit: 10000 yuan) (data source: meter net database) Xuesaitong for injection (freeze-drying) has the main functions of promoting blood circulation and removing blood stasis, promoting blood circulation and activating collaterals It can be used in hemiplegia due to apoplexy, blood stasis and sequelae of cerebrovascular diseases, chest arthralgia and heartache The occlusion of central retinal vein belongs to the syndrome of blood stasis The protection level of this product is level 2 The manufacturers of Xuesaitong for injection (freeze-drying) include Zhenbaodao pharmaceutical and kunyao group The main sales market of the product is in the terminal of public medical institutions in China In terms of market share, Zhenbaodao pharmaceutical accounts for 59% and kunyao group 41% Xuesaitong for injection (freeze-dried) is used for cerebrovascular disease In 2016, it ranked the third in the top 20 products in the terminal Chinese patent medicine cerebrovascular disease drug market in China's urban public hospitals, county-level public hospitals, urban community centers, township hospitals (referred to as China's public medical institutions)   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> Xuesaitong Soft Capsule, Shenbao tablet, 2016 double double breakthrough billion figure 2: Sales of Xuesaitong Soft Capsule in 2015-2016 (unit: 10000 yuan) (data source: minenet database) In 2015, the total sales volume of Xuesaitong Soft Capsule in the terminals of public medical institutions and urban retail pharmacies in China was about 890 million yuan, which rose to 1.07 billion yuan in 2016, with a growth rate of 20% Xuesaitong Soft capsule is mainly used for promoting blood circulation and removing blood stasis, promoting blood circulation and activating collaterals It can be used in the recovery period of meridians and collaterals in the ischemic stroke (cerebral infarction) caused by blood stasis block The symptoms include hemiplegia, hemiparalysis, skewness of mouth and tongue, and astringency of language The protection level of this product is level 2 The production enterprises of Xuesaitong Soft Capsule include zhenkunming Shenghuo Pharmaceutical (Group) and Kunming Pharmaceutical Group The main sales market of the product is in the terminal of public medical institutions in China In terms of market share, the leading enterprise Kunming Shenghuo Pharmaceutical (Group) has increased from 53% in 2015 to 54% At the end of retail drugstores in Chinese cities, the sales of Kunming Shenghuo Pharmaceutical (Group) exceeded 100 million yuan Xuesaitong Soft capsule is used for cerebrovascular disease In 2016, it ranked 12th among the top 20 products in the terminal Chinese patent medicine cerebrovascular disease drug market of public medical institutions in China, and third among the top 20 products in the terminal Chinese patent medicine cerebrovascular disease drug market of urban retail pharmacies in China Figure 3: sales volume of Shenbao tablet (unit: 10000 yuan) (data source: minenet database) from 2015 to 2016 Shenbao tablet has the main functions of harmonizing Yin and Yang, warming yang and tonifying kidney, strengthening and strengthening the body It can be used for lumbago and leg pain, low spirits, frequent night urination, chilly and chilly; white belt of women is clear and thin, and the protection level of the product is level 2 Shenbao tablet is the exclusive product of Jiangxi Huiren Pharmaceutical Co., Ltd the main sales market of this product is in China's urban retail drugstore terminals In 2015, the sales volume was about 850 million yuan, which rose to 1.05 billion yuan in 2016, with a growth rate of 24% Shenbao tablet is a kidney strengthening and kidney strengthening drug, ranking first among the top 20 products in the market of traditional Chinese medicine kidney strengthening and kidney strengthening drug at the terminal of Chinese urban retail drugstore in 2016   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> Shengxuebao mixture pushed into the" 500 million "echelon, with an increase rate of 35% Among the traditional Chinese medicine protection varieties with sales of more than 500 million yuan in 2016, Jintiange capsule, Shenyi capsule, compound Xuanju capsule, Shengxuebao mixture, Tongluo Qutong cream and Lianhuaqingwen capsule are all products that have stepped into the "500 million" Echelon from the "400 million" echelon, of which Shengxuebao mixture is the fastest growing one with a growth rate of 35% in 2016 Figure 4: sales volume of Shengxuebao mixture in 2015-2016 (unit: 10000 yuan) (data source: minenet database) the total sales volume of Shengxuebao mixture in China's public medical institutions terminal and China's urban retail drugstores terminal in 2015 was about 400 million yuan, rising to 540 million yuan in 2016, with a growth rate of 35% The main functions of Shengxuebao mixture are nourishing the liver and kidney, supplementing qi and promoting blood It can be used for asthenia of spirit caused by deficiency of liver and kidney, deficiency of Qi and blood, weakness of waist and knee, dizziness and tinnitus, palpitation, shortness of breath, insomnia, pharyngeal stem, lack of appetite, leukopenia caused by radiotherapy and chemotherapy For iron deficiency anemia, the protection level of the product is level 2 Shengxuebao mixture is the exclusive product of Xi'an Xingfu Pharmaceutical Co., Ltd., a Tsinghua German Its main sales market is at the end of public medical institutions in China This product is used to replenish blood In 2016, it ranked first among the top 20 products in the terminal Chinese patent medicine market of public medical institutions in China   none="shifuMouseDown('shifu_t_002')" style="margin: 1em auto; padding: 0.5em 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none; text-align: center; width: 670px; box-sizing: border-box !im portant; Word wrap: break word! Im portant; "> conclusion: of the 28 TCM protection varieties mentioned above, there are 17 products whose sales growth rate exceeds 10% in 2016, and only 4 products whose sales growth rate is negative From the data, the strength and potential of these TCM varieties with intellectual property rights in the market can not be underestimated In the 2017 edition of the national medical insurance catalogue, the restricted use scope of multiple traditional Chinese medicine injections has been increased Among the 28 protected varieties of traditional Chinese medicine, Xuesaitong (freeze-dried) for injection is limited to the second level and above medical institutions, salvianolic acid salt for injection is limited to the second level and above medical institutions and has clear diagnosis of coronary heart disease and angina pectoris, Shenqifuzheng injection is limited to be used simultaneously with radiotherapy and chemotherapy of lung cancer and gastric cancer, and Reduning injection is limited to the second level and above medical institutions for severe patients, Tanreqing injection is limited to the severe patients in the second level and above medical institutions, while Danshen injection (freeze-dried) is limited to the second level and above medical institutions, with clear diagnosis of coronary heart disease and angina pectoris Some insiders said that this restriction is expected to affect future sales to some extent, but how much is the specific impact? We can look forward to the data update in 2017 to let the market tell us the "truth" Facing the limitation of medical insurance, drug companies can only wait to die? No! In recent years, many pharmaceutical companies have spared no effort in the secondary development of large varieties of traditional Chinese medicine: step pharmaceutical mentioned in the 2017 half year report that the evidence-based medicine research of Naoxintong capsule is steadily advancing; Shanghai Kaibao also continues to increase the investment in research and development, creating conditions to accelerate the secondary development of xiantanreqing and the progress of research and development of series of varieties; Treasure Island pharmaceutical industry Said that the safety re evaluation of Xuesaitong for injection (freeze-drying) is also in normal progress These efforts will also become a driving force for the protection of traditional Chinese medicine varieties and large varieties of traditional Chinese medicine to continue to shine in the Chinese market and even on the world stage Source: CFDA official website, minenet, annual report of listed companies